# InnoPharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/innopharma

- Industry: Pharmaceuticals
- Headquarters: Piscataway, US
- Website: www.innopharmallc.com
- Total disclosed funding: $15M
- Latest round: Series A (Dec 1, 2011)
- Investors on record: 1

## About

InnoPharma, Inc. is a pharmaceutical company focused on developing innovative drug formulations and delivery systems that target healthcare challenges to enhance therapeutic efficacy and patient compliance.InnoPharma, Inc. specializes in pharmaceutical product development and was acquired by Pfizer Inc. in July 2014 for USD 225 mn, with the potential for an additional USD 135 mn in milestone payments. The firm is headquartered in Piscataway, US. The acquisition marked a significant pivot in the company's operations, aligning it with a major player in the pharmaceutical industry.Innopharma LLC specializes in the development and distribution of advanced pharmaceutical products and services aimed at addressing various healthcare challenges. Their core offerings include a range of innovative drug formulations and delivery systems designed to enhance therapeutic efficacy and patient compliance. These products are intended for use in both clinical and outpatient settings, catering to a diverse client base including hospitals, outpatient clinics, and specialty pharmacies. Innopharma's solutions are utilized by healthcare providers seeking to improve patient outcomes in therapeutic areas such as chronic diseases and acute medical conditions, primarily marketed in North America and select European markets.Innopharma generates revenue through direct sales of its pharmaceutical products and strategic partnerships with healthcare institutions. Transactions typically involve B2B agreements where hospitals and clinics procure supplies based on their patient needs. The company may also engage in subscription models for specific services, allowing healthcare providers to access ongoing support and product updates. Pricing structures for their offerings are designed to reflect the value provided to healthcare entities, fostering long-term relationships with clients to ensure a steady revenue stream from repeat business and new customer acquisitions.InnoPharma's strategy for future growth includes the continuation of product development and potential launches of new drug formulations. The company aims to expand its market presence in specific European regions by leveraging its partnership with Pfizer and utilizing the USD 225 mn from the acquisition to enhance its research capabilities and market outreach. The utilization of funds is expected to support ongoing development efforts and facilitate entry into new geographical markets by targeting strategic healthcare institutions for collaboration.

## Funding rounds

- Series A, Dec 1, 2011, $15M — Thomas, McNerney & Partners

## Investors

- Thomas, McNerney & Partners (https://capitalatlas.ai/funds/thomas-mcnerney-partners) — Series A